-$0.24 EPS Expected for Dicerna Pharmaceuticals Inc (DRNA) This Quarter

Share on StockTwits

Analysts forecast that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will report earnings of ($0.24) per share for the current quarter, Zacks reports. Three analysts have made estimates for Dicerna Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.13). Dicerna Pharmaceuticals reported earnings per share of ($0.92) in the same quarter last year, which indicates a positive year-over-year growth rate of 73.9%. The firm is scheduled to announce its next earnings report on Thursday, November 1st.

Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.26). The company had revenue of $1.55 million during the quarter, compared to analysts’ expectations of $1.79 million. Dicerna Pharmaceuticals had a negative return on equity of 97.39% and a negative net margin of 1,642.81%.

DRNA has been the subject of a number of analyst reports. Stifel Nicolaus upped their price target on Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. BidaskClub cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 8th. B. Riley increased their target price on Dicerna Pharmaceuticals from $10.00 to $13.50 and gave the company a “neutral” rating in a research note on Monday. Citigroup assumed coverage on Dicerna Pharmaceuticals in a research note on Thursday, September 13th. They set a “buy” rating and a $27.00 target price for the company. Finally, Chardan Capital reiterated a “hold” rating and set a $14.50 target price on shares of Dicerna Pharmaceuticals in a research note on Monday, August 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Dicerna Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $17.41.

NASDAQ DRNA opened at $16.80 on Tuesday. Dicerna Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $17.98. The company has a quick ratio of 5.40, a current ratio of 5.40 and a debt-to-equity ratio of 0.14.

In related news, Director Dennis Langer sold 14,531 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $16.00, for a total transaction of $232,496.00. Following the sale, the director now directly owns 29,064 shares of the company’s stock, valued at approximately $465,024. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider James B. Weissman sold 2,301 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $17.50, for a total value of $40,267.50. Following the sale, the insider now directly owns 26,781 shares in the company, valued at $468,667.50. The disclosure for this sale can be found here. Corporate insiders own 19.85% of the company’s stock.

Several hedge funds have recently bought and sold shares of DRNA. BlackRock Inc. raised its position in shares of Dicerna Pharmaceuticals by 839.8% during the 2nd quarter. BlackRock Inc. now owns 2,607,895 shares of the biopharmaceutical company’s stock valued at $31,946,000 after acquiring an additional 2,330,402 shares in the last quarter. Emerald Advisers Inc. PA raised its position in shares of Dicerna Pharmaceuticals by 2,002.5% during the 2nd quarter. Emerald Advisers Inc. PA now owns 603,508 shares of the biopharmaceutical company’s stock valued at $7,393,000 after acquiring an additional 574,804 shares in the last quarter. Northern Trust Corp raised its position in shares of Dicerna Pharmaceuticals by 719.5% during the 2nd quarter. Northern Trust Corp now owns 486,668 shares of the biopharmaceutical company’s stock valued at $5,962,000 after acquiring an additional 427,284 shares in the last quarter. Artal Group S.A. acquired a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter valued at approximately $4,063,000. Finally, Emerald Mutual Fund Advisers Trust raised its position in shares of Dicerna Pharmaceuticals by 247.6% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 526,859 shares of the biopharmaceutical company’s stock valued at $6,454,000 after acquiring an additional 375,288 shares in the last quarter. 87.02% of the stock is currently owned by institutional investors and hedge funds.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Further Reading: Beta

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply